Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.

Guardado en:
Detalles Bibliográficos
Autores principales: Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura, Yusuke Sakai, Yumi Itoh, Fuminori Sugihara, Yoshiharu Matsuura, Satoaki Matoba, Toru Okamoto, Junichi Takagi, Atsushi Hoshino
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6dacf0dd324f4db5afbaae20298e4ac1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/6dacf0dd324f4db5afbaae20298e4ac1

Ejemplares similares